The antibodies that scientists use to detect proteins in biological samples are supposed to come with validation images proving they work. Now, a comprehensive investigation suggests that nearly 19,000 of those images across 15 major suppliers show signs of manipulation — raising alarm about the reliability of one of biomedical research's most essential tools.
The report, compiled by Northwestern University scientific disinformation researcher Reese Richardson, catalogs 18,943 images across 17,495 antibody products from companies including Abcam, Thermo Fisher Scientific, MilliporeSigma, Novus Biologicals, GeneTex, and Santa Cruz Biotechnology, among others. The findings, reported August 25 by Chemical & Engineering News, follow a similar May investigation focused on Thermo Fisher's catalogue alone.
Richardson found suspicious patterns by downloading validation images — typically Western blots used to demonstrate that an antibody binds to its target protein — and increasing their contrast to reveal background noise. In genuine experiments, each Western blot produces unique random background noise. But Richardson discovered large groups of images where the background noise was identical while the protein band appeared to have been shifted up or down to match the product's target protein.
"The background noise is the exact same, but the band is moving around," Richardson told C&EN.
The scope is staggering. Six of the 15 companies responded to requests for comment, with each promising to review their catalogs. But the damage to scientific trust may already be done. Biochemists use antibodies across fields from cancer biology to neuroscience, and faulty validation images mean researchers may have unknowingly purchased reagents that don't perform as advertised.
Elisabeth Bik, an independent research-integrity consultant, called the situation an example of scientists being "misled on an enormous scale." The duplicated images across different vendors suggest they may originate from a common upstream supplier in the antibody supply chain, compounding questions about how quality control failed at multiple levels.
For researchers who have used these antibodies in published studies, the implications are unsettling: experimental results could be compromised, and potentially valuable findings may have gone undiscovered due to unreliable reagents.
